目的：探讨表皮生长因子(epidermal growth factor，EGF)对视网膜色素上皮(retinal pigment epithelial，RPE)细胞增殖和迁徙的影响。

方法：体外培养人RPE细胞株(ARPE-19细胞)，给予不同浓度EGF处理ARPE-19细胞，通过噻唑蓝(methyl thiazolyl tetrazolium，MTT)实验、5-溴脱氧尿苷(5-bromodeoxyuridine，BrdU)吸收实验和细胞划痕实验检测EGF对ARPE-19细胞活力、增殖和迁徙的影响； 通过Western blot法检测EGF对表皮生长因子受体(epidermal growth factor receptor，EGFR)和蛋白激酶B(protein kinase B，AKT)蛋白表达的影响。

结果：MTT实验显示50、100ng/mL EGF处理12h诱导ARPE-19细胞活力增加； BrdU吸收实验显示100ng/mL EGF处理24h诱导BrdU染色阳性ARPE-19细胞数增加； 细胞划痕实验显示100ng/mL EGF处理24h可以诱导ARPE-19细胞迁徙能力增加。Western blot检测显示使用10～100ng/mL EGF 处理细胞 12h或者100ng/mL EGF 处理细胞15～180min均可以诱导磷酸化EGFR(pEGFR)表达升高和总EGFR表达降低，同时也可以诱导磷酸化AKT(pAKT)表达升高，但是对总AKT表达无显著影响。

结论：EGF通过EGFR/AKT信号通路增加RPE细胞的活力、增殖和迁徙能力，可能对增殖性玻璃体视网膜病变中RPE细胞的异常增殖和迁徙起到重要作用。

METHODS: Human RPE cell lines(ARPE-19 cell)were treated with different doses of EGF. The methyl thiazolyl tetrazolium(MTT)assay was used to detect cell viability. The 5-bromodeoxyuridine(BrdU)incorporation assay was used to detect cell proliferation and the “scratch-wound assay” was used to detect cell migration ability. The epidermal growth factor receptor(EGFR)and protein kinase B(AKT)proteins were detected by Western blot.

RESULTS:The MTT assay results showed that treatment with 50 and 100ng/mL EGF for 12h increased ARPE-19 cell viability. The BrdU incorporation assay and the “scratch-wound assay” showed that treatment with 100ng/mL EGF for 24h increased ARPE-19 cell proliferation and migration. The Western blot results showed that treatment with 10-100ng/mL EGF for 12h or 100ng/mL EGF for 15-180min increased phosphorylation levels of EGFR and decreased total levels of EGFR. Similarly, treatment with 10-100ng/mL EGF for 12h or 100ng/mL EGF for 15-180min increased phosphorylation levels of AKT, but not affected total levels of AKT.

CONCLUSION: EGF affects ARPE-19 cell viability, proliferation and migration through inducing phosphorylation of the EGFR/AKT signaling pathway. The EGFR/AKT signaling pathway might play an important role in abnormal proliferation and migration of RPE cells in proliferative vitreoretinopathy.